Selected engineering and physicochemical aspects of systemic drug delivery by inhalation

Current Pharmaceutical Design

Volumn 22, Issue 17, 2016, Pages 2453-2462

  Sosnowski, Tomasz R ^a  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Aerosol; Air blood barrier; Deposition; Inhalation; Particles; Surfactant

Indexed keywords

DRUG CARRIER; NANOCARRIER; RECOMBINANT HUMAN INSULIN; DRUG;

AEROSOL; AIRBORNE PARTICLE; ANATOMICAL CONCEPTS; BIOMEDICAL ENGINEERING; BREATHING MECHANICS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; DRY POWDER INHALER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RESPIRATORY FUNCTION; REVIEW; VISCOSITY; ADMINISTRATION AND DOSAGE; CHEMISTRY;

ADMINISTRATION, INHALATION; AEROSOLS; BIOMEDICAL ENGINEERING; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84974678232     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160128145644     Document Type: Review

References (94)

1. th June 2015].
2. Wichmann HE, Peters A. Epidemiological evidence of the effects of ultrafine particle exposure. Phil Trans R Soc Lond A 2000; 358: 2751-69.
3. Becker DE, Rosenberg M. Nitrous oxide and the inhalation anesthetics. Anesth Prog 2008; 55(4): 124-31.
4. Kreyling WG, Geiser M. Dosimetry of inhaled nanoparticles. In: Marijnissen J, Gradoń L, Eds. Nanoparticles in environment and medicine. Dordrecht: Springer 2010; pp: 145-71.
5. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996; 19(1): 3-36.
6. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004; 1: 338-44.
7. Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Del Rev 2006; 58: 1061-75.
8. Siekmeier R, Scheuch G. Treatment of systemic diseases by inhalation of biomolecule aerosols. J Physiol Pharmacol 2009; 60 (Suppl 5): 15-26.
9. Hickey AJ. Back to the future: inhaled drug products. J Pharm Sci. 2013; 102(4): 1165-72.
10. Laube BL. Aerosolized medications for gene and peptide therapy. Respir Care 2015; 60(6): 806-24.
11. Bausewein C, Simon ST. Inhaled nebulized and intranasal opioids for the relief of breathlessness. Curr Opin Support Palliat Care 2014; 8(3): 208-12.
12. Kampa M, Castanas E. Human health effects of air pollution. Environ Pollut 2008; 51(2): 362-7.
13. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res 2013; 3(1): 42-62.
14. Riese P, Sakthivel P, Trittel S, Guzmán CA. Intranasal formulations: promising strategy to deliver vaccines. Expert Opin Drug Deliv 2014; 11(10): 1619-34.
15. Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release 2014; 189: 133-40.
16. USP Chapter <601> Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers; Rockville: US Pharmacopeial Convention 2008.
17. th ed. Strasbourg: European Directorate for the Quality of Medicines and Healthcare 2013.
18. Kobayashi Y, Yasuba H, Kudou M, Hamada K, Kita H. Esophageal candidiasis as a side effect of inhaled fluticasone propionate dry powder: recovery by switching over to hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP). Int J Clin Pharmacol Ther 2006; 44(5): 193-7.
19. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006; 61(5): 518-26.
20. Zanen P. Targetting aerosols to disease areas. In: Gradoń L, Marijnissen J. Eds. Optimization of aerosol drug delivery. Dordrecht: Kluwer 2003; pp. 243-76.
21. Newman S. Respiratory drug delivery. Essential theory and practice. Richmond: RDD Online-VCU 2009.
22. Ikeda T. Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways. Br J Pharmacol 2012; 166(6): 1804-14.
23. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy a systemic review and meta-analysis. Arch Intern Med 1999; 159: 941-55.
24. White M, Crisalida T, Li H, Economides A, Kaliner M. Effects of long term inhaled corticosteroid on adrenal function in a patient with asthma. Ann Allergy Asthma Immunol 2006; 96: 437-44.
25. International Council for Radiological Protection. Human respiratory tract model for radiological protection. ICRP Publication 66 Ann ICRP 1994; 24: 231.
26. National Council for Radiological Protection. Deposition, retention and dosimetryof inhaled radioactive substances. 1997; Report No. 125.
27. Asgharian B, Hofmann W, Bergmann R. Particle deposition in a multiple-path model of the human lung. Aerosol Sci Technol 2001; 34: 332-9.
28. MPPD software. http: //www.ara.com/products/mppd.htm [cited: 17.06.2015]
29. Finlay WH, Martin AE. Recent advances in predictive understanding of respiratory tract deposition. J Aerosol Med Pulm Drug Deliv 2008; 21: 189-206.
30. ARLA. http: //www.mece.ualberta.ca/arla/deposition_calculator. html [cited: 17.06.2015]
31. Moskal A, Gradoń L. Temporary and spatial deposition of aerosol particles in the upper human airways during breathing cycle. J Aerosol Sci 2002; 33 (11): 1525-39.
32. Fresconi FE, Prasad AK. Secondary velocity fields in the conducting airways of the human lung. J Biomech Eng 2007; 129(5): 722-32.
33. Sosnowski TR, Moskal A, Gradoń L. Dynamics of oropharyngeal aerosol transport and deposition with the realistic flow pattern. Inhal Toxicol 2006; 18(10): 773-80.
34. Sosnowski TR, Moskal A, Gradon L. Mechanims of aerosol particle deposition in the oro-pharynx under non-steady airflow. Ann Occup Hyg 2007; 51(1): 19-25.
35. Borgström L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 2006; 19(4): 473-83.
36. Desai TR, Hancock REW, Finlay WH. A facile method of delivery of liposomes by nebulization. J Control Release 2002; 84(1-2): 69-78.
37. Sosnowski TR, Kurowska A, Butruk B, Jabłczyńska K. Spraying of cell colloids in medical atomizers. Chem Eng Transact 2013; 32: 2257-62.
38. McCallion ONM, Taylor KMG, Thomas M, Taylor AJ. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res 1995; 12: 1682-8.
39. Broniarz-Press L, Sosnowski TR, Matuszak M, Ochowiak M, Jabłczyńska K. The effect of shear and extensional viscosities on atomization of Newtonian and non-Newtonian fluids in ultrasonic inhaler. Int J Pharmaceutics 2015; 485: 41-9.
40. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: A report from the Aerosol Drug Management Improvement Team. Respir Med 2006; 100: 1479-94.
41. Inhaler Error Steering Committee, Price D, Bosnic-Anticevich S, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med 2013; 107: 37-46.
42. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Resp J 2002; 19: 246-51.
43. Islam N, Gladki E. Dry powder inhalers (DPIs)-a review of device reliability and innovation. Int J Pharm 2008; 360: 1-11.
44. Sosnowski TR, Giżyńska K, Żywczyk Ł. Fluidization and break-up of powder particle aggregates during constant and pulsating flow in converging nozzles. Coll Surf A: Physicochem Eng Asp 2014; 441: 905-11.
45. Gradoń L, Sosnowski TR. Formation of particles for dry powder inhalers. Adv Powder Technol 2014; 25(1): 43-55.
46. Gac J, Sosnowski TR, Gradoń L. Turbulent flow energy for aerosolization of powder particles. J Aerosol Sci 2008; 39: 113-26.
47. Gradoń L. Resuspension of particles from surfaces: technological, environmental and pharmaceutical aspects. Adv Powder Technol 2009; 20 (1): 17-28.
48. Balducci AG, Cagnani S, Sonvico F, et al. Pure insulin highly respirable powders for inhalation. Eur J Pharm Sci 2014; 51: 110-7.
49. Jabłczyńska K, Janczewska M, Kulikowska A, Sosnowski TR. Preparation and characterization of biocompatible polymer particles as potential nanocarriers for inhalation therapy. Int J Polymer Sci 2015; 2015: 763020.
50. Chew NY, Chan HK. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler. J Aerosol Med 2001; 14(4): 495-501.
51. Moskal A, Sosnowski TR. Dynamics of aerosol pulse in a simplified mouth-throat geometry and its significance for inhalation drug delivery. Inz Chem Proc 2009; 30: 545-58.
52. Martin GP, Marriott C, Zeng XM. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations. Pharm Res 2007; 24(2): 361-9.
53. Hampson NB, Mueller MP. Reduction in patient timing errors using a breath-activated metered dose inhaler. Chest 1994; 106(2): 462-5.
54. Price D, Thomas M, Mitchell G, Niziol C, Featherstone R. Improvement of asthma control with a breath-actuated pressurised metered dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-actuated device. Respirat Med 2003; 97(1): 12-9.
55. Fischer A, Stegemann J, Scheuch G, Siekmeier R. Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur J Med Res 2009; 14 (Suppl 4): 71-7.
56. Denyer J, Dyche T. The Adaptive Aerosol Delivery (AAD) technology: past, present, and future. J Aerosol Med Pulm Drug Deliv 2010; 23 (Suppl 1): S1-10.
57. Iskandar F, Gradon L, Okuyama K. Control of the morphology of nanostructured particles prepared by the spray drying of a nanoparticle sol. J Colloid Interface Sci 2003; 265(2): 296-303.
58. Suhendi A, Nandiyanto AB, Munir MM, Ogi T, Gradon L, Okuyama K. Self-assembly of colloidal nanoparticles inside charged droplets during spray-drying in the fabrication of nanostructured particles. Langmuir 2013; 29(43): 13152-61.
59. Oberdörster G. Lung dosimetry: pulmonary clearance of inhaled particles. Aerosol Sci Tech 1993; 18: 279-89.
60. Bernardin MP, Lehnert BE. Model of particle-alveolar macrophage relationships during alveolar clearance of a low lung burden of instilled particles. J Aerosol Sci 1995; 26(2): 319-33.
61. Podgórski A, Grado L. An improved mathematical model of hydrodynamical self-cleansing of pulmonary alveoli. Ann Occup Hyg 1993; 37(4): 347-65.
62. Grado L, Podgórski A. Displacement of alveolar macrophages in air space of human lung. Med Biol Eng Comput 1995; 33(4): 575-81.
63. Sosnowski TR. Nanosized and nanostructured particles in pulmonary drug delivery. J Nanosci Nanotechnol 2015; 15: 3476-87.
64. Grado L, Podgórski A. Hydrodynamical model of pulmonary clearance. Chem Eng Sci 1989; 44: 741-9.
65. Grado L, Podgórski A, Sosnowski TR. Experimental and theoretical investigations of transport properties of DPPC monolayer. J Aerosol Med 1996; 9: 357-67.
66. Sosnowski TR, Grado L Podgorski A. Influence of insoluble aerosol deposits on the surface activity of the pulmonary surfactant: a possible mechanism of alveolar clearance retardation? Aerosol Sci Technol 2000; 32(1): 52-60.
67. Podgórski A, Sosnowski TR. Assessment of the pulmonary toxicity of inhaled gases and particles with physicochemical methods. Int J Occup Safety Ergon 1999; 5(3): 431-47.
68. Podgórski A, Sosnowski TR, Grado L. Deactivation of the pulmonary surfactant dynamics by toxic aerosols and gases. J Aerosol Med 2001; 14(4): 455-66.
69. Kramek-Romanowska K, Odziomek M, Sosnowski TR. Dynamic tensiometry studies on interactions of novel therapeutic inhalable powders with model pulmonary surfactant at the air-water interface. Coll Surf A: Physicochem Eng Aspects 2015; 480: 149-58.
70. Sosnowski T.R. Sorption-induced Marangoni microflows in the pulmonary surfactant system. Inz Chem Process 2001; 22(2): 251-67.
71. Schürch S, Gehr P, Im Hof V, Geiser M, Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol 1990; 80(1): 17-32.
72. Gehr P, Green FHY, Geiser M, Im Hof V, Lee NM, Schürch S. Airway surfactant, a primary defense barrier: mechanical and immunological aspects. J Aerosol Med 1996; 9(2): 163-18.
73. Kondej D, Sosnowski TR. Alteration of biophysical activity of pulmonary surfactant by aluminosilicate nanoparticles. Inhal Toxicol 2013; 25(2): 77-83.
74. Kondej D, Sosnowski TR. Physicochemical mechanisms of mineral nanoparticles effects on pulmonary gas/liquid interface studied in model systems. Physicochem Probl Miner Process 2014; 50(1): 55-67.
75. Sosnowski TR, Grado L, Iskandar F, Okuyama K. Interaction of deposited aerosol particles with the alveolar liquid layer. In: Grado L, Marijnissen J. Eds. Optimization of aerosol drug delivery. Dordrecht: Kluwer 2003; pp. 205-16.
76. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Del Rev 2011; 63(3): 136-51.
77. Prietl B, Meindl C, Roblegg E, Pieber TR, Lanzer G, Fröhlich E. Nano-sized and micro-sized polystyrene particles affect phagocyte function. Cell Biol Toxicol 2014; 30(1): 1-16.
78. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends in Biotechnol 2007; 25(12): 563-70.
79. Yang W, Peters JI, Williams III RO. Inhaled nanoparticles-a current review. Int J Pharm 2008; 356 (1-2): 239-47.
80. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 2009; 29 (1): 196-212.
81. Oberdörster G, Sharp Z, Atudorei V, et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 2004; 16(6-7): 437-45.
82. Sahu SK, Tiwari M, Bhangare RC, Pandit GG. Particle size distribution of mainstream and exhaled cigarette smoke and predictive deposition in human respiratory tract. Aerosol Air Qual Res 2013; 13(1): 324-32.
83. Fuoco FC, Buonanno G, Stabile L, Vigo P. Influential parameters on particle concentration and size distribution in the mainstream of e-cigarettes. Environ Pollut 2014; 184: 523-9.
84. Sosnowski TR. Predicted lung deposition of electronic cigarette aerosols. J Aerosol Med Pulm Drug Del 2015; 28(3): A28-9.
85. Palazzolo DL. Electronic cigarettes and vaping: a new challenge in clinical medicine and public health. A literature review. Front Publ Health 2013; 1: article 56 (20 pages).
86. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation 2014; 129(19): 1972-86.
87. Dinh K, Myers DJ, Glazer M, et al. In vitro aerosol characterization of Staccato(®) Loxapine. Int J Pharm 2011; 403(1-2): 101-8.
88. Nordstrom K, Allen MH. Alternative delivery systems for agents to treat acute agitation: progress to date. Drugs 2013; 73(16): 1783-92.
89. Valdes J, Shipley T, Rey JA. Loxapine inhalation powder (adasuve): a new and innovative formulation of an antipsychotic treatment for agitation. Pharm Ther 2014; 39(9): 621-3, 648.
90. Santos CT, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther 2014; 36(8): 1275-89.
91. Utell MJ, Beckett WS. Implications for occupational exposure to particulate matter. Clin Occup Environ Med 2006; 5(4): 883-93.
92. Rushton L. Chronic obstructive pulmonary disease and occupational exposure to silica. Rev Environ Health 2007; 22(4): 255-72.
93. Oberdörster G. Lung particle overload: implications for occupational exposures to particles. Regul Toxicol Pharmacol 1995; 21(1): 123-35.
94. Klonoff DC. Afrezza inhaled insulin: the fastest-acting FDAapproved insulin on the market has favorable properties. J Diabetes Sci Technol 2014; 8(6): 1071-3.